Skip to main content

Most Patients With Dry Eye Suffer Dry Eye Flares1-3

  • Dry Eye Flares are rapid-onset, inflammation-driven responses to a variety of triggers, which may not be adequately managed with a patient’s ongoing maintenance therapy, such as artificial tears and daily, chronic Rx therapies4-7
  • Most patients with Dry Eye suffer from short-term, episodic exacerbations—Dry Eye Flares; many patients don’t suffer from continuous symptoms1-3
Woman who may be suffering with Dry Eye Flares
approx 80%

OF PATIENTS WITH DRY EYE SUFFER FLARES1-3*

=45%

OF PATIENTS With Dry Eye REPORT HAVING PRIMARILY FLARES INSTEAD OF CONTINUOUS SYMPTOMS3*

Yet ECPs report that

only 40%

of patients suffer from Flares.8† As patients may not be discussing their Flares during regularly scheduled visits, IT’S IMPORTANT TO ASK YOUR PATIENT IF THEY ARE SUFFERING DRY EYE FLARES.

Patients with Dry Eye Want A Treatment That Delivers Rapid Relief8‡

*Data based on:

Study of Dry Eye Sufferers conducted by Multi-sponsor Surveys, Inc, trended series;
• 2018 study (N=751)2; 2020 study (N=774)3
• 2018 Lieberman Dry Eye Patient Survey (N=297)1,2

Based on 2020 Reason Research, LLC, ECP Survey (N=201; n=101 OPHs and n=100 OPTs).

Based on 2020 Lieberman Dry Eye Patient Survey (N=500).

ECPs=eye care professionals; OPHs=ophthalmologists; OPTs=optometrists.

The Pathophysiology
of Dry Eye Flares

Dry Eye may be initiated by desiccating and osmotic stress and then is perpetuated by a cycle of ocular surface tissue inflammation, tear film instability, and hyperosmolarity.4 It is well-known that inflammation plays a key role in the pathogenesis of Dry Eye. Similarly, data support inflammation as a key driver of Dry Eye Flares.9

Dry Eye flares begin when cells of the ocular surface encounter a danger signal, such as refractive surgeries, or an environmental trigger, eliciting a rapid innate immune response.

The innate response may be followed by the slower adaptive response. Once an adaptative response is established, future flares may occur at a lower stress threshold, with inflammation maintained over a longer period.9

EYSUVIS addresses the pathogenesis of DRY EYE and Dry eye flares By DOWN-regulating both the innate and adaptative immune response pathways9

Peer-Reviewed Publication

References: 1. Brazzell RK, Zickl L, Farrelly J, et al. Prevalence and characteristics of dry eye flares: a patient questionnaire survey. Presented at: AAO 2019: October 12-15, 2019; San Francisco, CA. 2. Brazzell RK, Zickl L, Farrelly J, et al. Prevalence and characteristics of symptomatic dry eye flares: results from patient questionnaire surveys. Poster presented at: AAOPT 2019: October 23-27, 2019; Orlando, FL. 3. 2020 Study of Dry Eye Sufferers. Conducted by Multi-sponsor Surveys, Inc. 4. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS pathophysiology report. Ocul Surf. 2017;15:438-510. 5. Amparo F, Dana R. Web-based longitudinal remote assessment of dry eye symptoms. Ocul Surf. 2018;16(2):249-253. 6. Iyer JV, Lee S-L, and Tong L. The dry eye disease activity log study. The Scientific World Journal. 2012;589875. 7. Kim Y, Paik HJ, Kim MK, et al. Short-term effects of ground-level ozone in patients with dry eye disease: a prospective clinical study. Cornea. 2019;38(12):1483-1488. 8. Data on file. Kala Pharmaceuticals. Watertown, MA. 9. Perez VL, Stern ME, Pflugfelder SC. Inflammatory basis for dry eye disease flares. Exp Eye Res. 2020; In press.

Important Safety Information

Contraindication:

EYSUVIS, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

Warnings and Precautions:

Delayed Healing and Corneal Perforation: Topical corticosteroids have been known to delay healing and cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation. The initial prescription and each renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining.

Intraocular Pressure (IOP) Increase: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, as well as defects in visual acuity and fields of vision. Corticosteroids should be used with caution in the presence of glaucoma. Renewal of the medication order should be made by a physician only after examination of the patient and evaluation of the IOP.

Cataracts: Use of corticosteroids may result in posterior subcapsular cataract formation.

Bacterial Infections: Use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, corticosteroids may mask infection or enhance existing infection.

Viral Infections: Use of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungal Infections: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion must be considered in any persistent corneal ulceration where a corticosteroid has been used or is in use.

Adverse Reactions:

The most common adverse drug reaction following the use of EYSUVIS for two weeks was instillation site pain, which was reported in 5% of patients.

Indication

EYSUVIS is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.

View full Prescribing Information.